AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the ...
AstraZeneca is committed to developing medicines to help every patient with lung cancer. We have two approved medicines and a growing pipeline that targets genetic changes in tumour cells and boosts the power of the immune response against cancer.
AstraZeneca PLC's (LON:AZN) Imfinzi cancer treatment has cleared another regulatory hurdle after the US Food and Drug Administration accepted a supplemental Biologics License Application (sBLA) for the treatment of certain lung cancer patients.
LONDON (Alliance News) - Hutchison China MediTech Ltd said Tuesday it and AstraZeneca PLC presented safety and clinical data of combinations of savolitinib at the World Conference on Lung Cancer in Yokohama, Japan.